PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

Wang, Xing; Wen, Dingke; Chen, Yuqi; Ma, Lu; You, Chao

doi:10.1186/s12933-022-01542-4

Cardiovascular Diabetology

Table 1 Characteristics of studies included in the systematic review

From: PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

Trial	Register number	Patients, n	Male (%)	Age, years*	BMI, kg/m²*	Diabetes (%)*	Follow up (weeks)	Baseline for LDL-C (mg/dl)*	Characteristics of patients	Background therapy	Administration of PCSK9 modulators
PACMAN-AMI 2022	NCT03067844	300	81.0	58.6	28.2	12.5	52 weeks	150.9	Adults with STEMI or NSTEMI	High-intensity statin therapy	Alirocumab 150 mg every 2 weeks
ODYSSEY OUTCOMES 2018	NCT01663402	18,924	74.8	58.6	28.5	29.1	2.8 years	92	Adults with an acute coronary syndrome 1 to 12 months before randomization	Maximally tolerated statin therapy	Alirocumab 75 mg every 2 weeks
ODYSSEY COMBO I 2015	NCT01644175	316	65.8	63.0	32.0	39.3	52 weeks	106.0	Adults with established CHD or CHD risk equivalents	Maximally tolerated statin therapy	Alirocumab 75 mg every 2 weeks
ODYSSEY COMBO II 2015	NCT01644188	720	73.6	61.3	30.3	31.5	52 weeks	104.4	Adults with established CHD or CHD risk equivalents	Maximally tolerated statin therapy	Alirocumab 75 mg every 2 weeks
ODYSSEY LONG TERM 2015	NCT01507831	2,341	63.3	60.6	30.5	33.9	78 weeks	121.9	Adult patients with heterozygous familial hypercholesterolemia or with established CHD or a CHD risk equivalent	Maximally tolerated statin therapy	Alirocumab 150 mg every 2 weeks
FOURIER 2017	NCT01764633	27,564	75.4	62.5	NR	36.5	2.2 years	92	Adults with clinically evident ASCVD	High-intensity or moderate-intensity statin therapy	Evolocumab 140 mg every 2 weeks or 420 mg every month
GLAGOV 2016	NCT01813422	968	72.2	59.8	29.5	21.5	78 weeks	92.4	Adults with angiographic coronary disease	High-intensity or moderate-intensity statin therapy	Evolocumab 420 mg every month
ORION- 10 2020	NCT03399370	1,561	69.3	65.7	NR	42.4	540 days	104.8	Adults with ASCVD	Maximally tolerated statin therapy	Inclisiran 284 mg day 1, day 90, and every 6 months thereafter
ORION- 11 2020	NCT03400800	1,617	71.7	64.8	NR	33.7	540 days	103.7	Adults with ASCVD or an ASCVD risk equivalent	Maximally tolerated statin therapy	Inclisiran 284 mg day 1, day 90, and every 6 months thereafter

NR not reported, BMI body-mass index, LDL-C low-density lipoprotein cholesterol, CHD coronary heart disease, ASCVD atherosclerotic cardiovascular disease, STEMI ST-elevation myocardial infarction, NSTEMI: non-ST-elevation myocardial infarction
^*from control group

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com